Call | Senior Fellowship (SF) |
Programme | EDCTP2 |
Start Date | 2020-04-01 |
End Date | 2025-03-31 |
Project Code | TMA2018SF-2467 |
Status | Active |
The Individualized Multi-/Extensively Drug-Resistant Tuberculosis Treatment Strategy Study (InDEX)
Institution | Country |
---|---|
Centre for the Aids Programme of Research in South Africa (CAPRISA) | South Africa |
Call | Senior Fellowship (SF) |
Programme | EDCTP1 |
Start Date | 2013-01-01 |
End Date | 2014-12-31 |
Project Code | TA.2011.40200.044 |
Status | Completed |
Improving retreatment success of tuberculosis
To determine if a moxifloxacin-containing regimen [isoniazid (H), rifampin (R), pyrazinamide (Z), moxifloxacin (M)] of 24 weeks duration is superior to a control regimen [isoniazid (H), rifampicin(R), pyrazinamide(Z), ethambutol(E)] of 32 weeks duration in improving treatment outcomes in patients with recurrent TB
Institution | Country |
---|---|
University of KwaZulu-Natal (UKZN) | South Africa |
Name | Institution | Country |
---|---|---|
Gavin John Churchyard | Aurum Institute for Health Research | South Africa |
Wafaa El-Sadr | Columbia University | United States |
Sarah Fortune | Harvard School of Public Health | United States |
Gerald Friedland | Yale University | United States |
William Jacobs | Albert Einstein College of Medicine | United States |
Salim S. Abdool Karim | University of KwaZulu-Natal (UKZN) | United States |
Randomised controlled trial
CAPRISA eThekwini Clinical Research Site (eCRS) |
Title | University | Start Date | End Date |
---|---|---|---|
Improving Retreatment Success in TB | University of KwaZulu-Natal (UKZN) | 2014-02-03 | 2016-12-30 |
Centre for the AIDS Programme of Research in South Africa
Deputy Director
Type | Name | Title | University | Start Date | End Date |
---|---|---|---|---|---|
Postgraduate | Rubeshan Perumal | Dr | University of KwaZulu-Natal | 2012 | 2019 |
Postgraduate | Amrita Daftary | Dr | Columbia University, NY | 2013 | 2016 |
Postgraduate | Marian Loveday | Dr | Medical Research Council | 2014 | 2016 |
Role | Committee/board | Start Date | End Date |
---|---|---|---|
Member | Bedaquiline Access Program | 2013 | 2019 |
Member | Southern African HIV Clinicians society | 2014 | |
SA MRC Silver Award for lifetime contribution to research | SA Medical Research Council | 2018 | |
Protocol Team | Adult Aids Clinical Trials Group – Study A5289, A5300 | 2008 | 2013 |
Protocol Co-chair | Adult Aids Clinical Trials Group – Study A5319 | ||
Member | The Academy of Science of South Africa (ASSAf) | 2014 | |
Member | DSMB STREAM Study, international | 2015 | |
Member | International Union against TB and Lung Disease Ethics Advisory | 2015 | |
Member | International Society of Infectious Diseases | 2015 | |
Board Member | South African HIV Clinicians Society | 2016 | |
Member | India TB Research Consortium | 2017 | |
Member | International Aids Society | 2013 |
Institution | Degree | Year |
---|---|---|
University of Durban-Westville, South Africa | BS | 1979-12-30 |
university of Natal, South Africa | MBBS | |
College of South Africa, South Africa | Diploma | |
University of Witwatersrand, South Africa | Diploma | |
University of Witwatersrand, South Africa | Diploma | |
University of Witwatersrand, South Africa | Diploma | |
Columbia University, United States | MS | |
University of KwaZulu-Natal, South Africa | PhD |
Tuberculosis (TB)
Open access full text article.
Moxifloxacin, an 8-methoxy quinolone, is an important drug in the treatment of multidrug-resistant tuberculosis and is being investigated in novel drug regimens with pretomanid, bedaquiline, and pyrazinamide, or rifapentine, for the treatment of drug-susceptible tuberculosis. Early results of these studies are promising. Although current evidence does not support the use of moxifloxacin in treatment-shortening regimens for drug-susceptible tuberculosis, it may be recommended in patients unable to tolerate standard first-line drug regimens or for isoniazid monoresistance. Evidence suggests that the standard 400-mg dose of moxifloxacin used in the treatment of tuberculosis may be suboptimal in some patients, leading to worse tuberculosis treatment outcomes and emergence of drug resistance. Furthermore, a drug interaction with the rifamycins results in up to 31% reduced plasma concentrations of moxifloxacin when these are combined for treatment of drug-susceptible tuberculosis, although the clinical relevance of this interaction is unclear. Moxifloxacin exhibits extensive interindividual pharmacokinetic variability. Higher doses of moxifloxacin may be needed to achieve drug exposures required for improved clinical outcomes. Further study is, however, needed to determine the safety of proposed higher doses and clinically validated targets for drug exposure to moxifloxacin associated with improved tuberculosis treatment outcomes. We discuss in this review the evidence for the use of moxifloxacin in drug-susceptible tuberculosis and explore the role of moxifloxacin pharmacokinetics, pharmacodynamics, and drug interactions with rifamycins, on tuberculosis treatment outcomes when used in first-line tuberculosis drug regimens.
Name | Country | Institution |
---|---|---|
Nesri Padayatchi | South Africa | Centre for the AIDS Programme of Research in South Africa (CAPRISA) |
Name | Country | Institution |
---|---|---|
Neel Rajnikant Gandhi | United States | Emory University |
Koleka Mlisana | South Africa | University of KwaZulu-natal |
Kogieleum Naidoo | South Africa | CAPRISA |
Nesri Pdayatchi | South Africa | CAPRISA |
Name | Country | Institution |
---|---|---|
Nesri Padayatchi | South Africa | Centre for the AIDS Programme of Research in South Africa (CAPRISA) |
Name | Country | Institution |
---|---|---|
Nesri Padayatchi | South Africa | Centre for the AIDS Programme of Research in South Africa (CAPRISA) |
Kogieleum Naidoo | South Africa | Centre for the AIDS Programme of Research in South Africa (CAPRISA) |
Max R O’Donnell | United States | Columbia University Medical Center |